Business Context and Reporting Period
Company: Palatin Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2008
Business Overview: Palatin is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific peptide and small molecule therapeutics. Key programs include melanocortin (MC)-based therapeutics for hemorrhagic shock, sexual dysfunction, and obesity (in collaboration with AstraZeneca), and natriuretic peptide receptor A (NPRA) agonists for hypertension and heart failure. The company also holds a suspended collaboration for NeutroSpec, an imaging agent for infection.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2007 |
|---|---|---|---|
| Revenues | $746,957 | $10,467,523 | $11,768,247 |
| Net Loss | $(5,111,194) | $(9,142,074) | $(21,647,051) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.11) | $(0.30) |
| Operating Cash Flow | N/A | $(15,858,501) | $(13,159,683) |
| Cash and Cash Equivalents (End of Period) | $14,223,326 | $14,223,326 | $40,576,297 |
| Total Assets | $24,867,402 | $24,867,402 | $42,781,234 |
| Accumulated Deficit | $(197,337,143) | $(197,337,143) | $(188,195,069) |
Liquidity: As of March 31, 2008, the company held $14.2 million in cash and cash equivalents and $3.4 million in available-for-sale investments. Management believes these resources, combined with expected collaboration receipts, are sufficient to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the three months ended March 31, 2008, dropped to $0.7 million from $3.1 million in the prior year period. This decrease is primarily due to the termination of the collaboration agreement with King Pharmaceuticals in December 2007, which previously accounted for the majority of revenue. Revenue from the AstraZeneca collaboration increased to 98% of total revenue for the quarter.
- Reduced Net Loss: The net loss for the nine months ended March 31, 2008, was $9.1 million, a significant improvement from the $21.6 million loss in the same period in 2007. This improvement was driven by a substantial reduction in Research and Development (R&D) expenses ($16.3 million vs. $29.8 million) following the King termination and workforce reductions.
- Cash Position: Cash and cash equivalents decreased by approximately $17.2 million during the nine-month period, reflecting net cash used in operating activities of $15.9 million and investing activities of $1.2 million.
- Income Tax Benefit: The company recognized a tax benefit of $1.3 million for the nine months ended March 31, 2008, resulting from the sale of New Jersey state net operating loss carryforwards.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur a significant loss for the fiscal year ending June 30, 2008. The company anticipates spending between $3 million and $4 million on direct costs for laboratory research, preclinical studies, and clinical trials during fiscal 2008.
- Development Pipeline:
- Bremelanotide: Repositioned for hemorrhagic shock; Phase 3 trials for sexual dysfunction discontinued. An Investigational New Drug (IND) application for hemorrhagic shock is anticipated in the first half of calendar 2009.
- NPRA Agonist (PL-3994): Completed Phase 1 safety trial; Phase 2A study for hypertension is planned to begin in the current quarter.
- NeutroSpec: Sales and marketing remain suspended pending evaluation of future development alternatives following serious adverse events.
- Subsequent Event: On May 12, 2008, the company reduced its workforce by approximately 30%, incurring approximately $400,000 in severance costs to be recorded in the quarter ended June 30, 2008.
- Risks: The company has no experience in marketing or selling products and relies on partners. There is no assurance of achieving profitability. Continued negative cash flows require successful financing or strategic collaborations. Regulatory approval for product candidates is uncertain.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of revenue streams given that 98% of Q1 2008 revenue came from AstraZeneca, following the loss of the King Pharmaceuticals partnership.
- Liquidity Runway: Confirm the company's ability to fund operations for the next 12 months without additional equity financing, given the $17.2 million cash burn over the last nine months.
- Workforce Reduction Impact: Assess the impact of the 30% workforce reduction announced in May 2008 on the timeline for clinical trials and product development.
- NeutroSpec Status: Monitor updates regarding the suspended NeutroSpec program and the potential for resuming sales or further development.
- Legal Settlement: Review the terms of the January 2008 settlement with Competitive Technologies, Inc., which resolved disputes over intellectual property rights.